Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8401704 | 0.91 | HDAC1 (0.89) | HDAC1HDAC3HDAC2MAPK1NCOR2 | |
| SCHEMBL4715033 | 0.87 | HDAC1 (0.70) | HDAC1HDAC3HDAC2MAPK1NCOR2 | |
| SCHEMBL1060598 | 0.86 | HDAC1 (0.79) | HDAC1HDAC3HDAC2MAPK1NCOR2 | |
| Dinaline SCHEMBL93636 | 0.86 | HDAC1 (0.79) | HDAC1HDAC3HDAC2MAPK1NCOR2 | |
| Dinaline SCHEMBL29354254 | 0.86 | HDAC1 (0.79) | HDAC1HDAC3HDAC2MAPK1NCOR2 | |
| SCHEMBL407834 | 0.85 | HDAC1 (1.00) | HDAC1HDAC3HDAC2MAPK1NCOR2 | |
| SCHEMBL30363156 | 0.85 | HDAC1 (1.00) | HDAC1HDAC3HDAC2MAPK1NCOR2 | |
| SCHEMBL23500754 | 0.84 | HDAC1 (0.83) | HDAC1HDAC3HDAC2MAPK1NCOR2 | |
| Dinaline SCHEMBL10373837 | 0.84 | HDAC1 (0.77) | HDAC1HDAC3HDAC2MAPK1NCOR2 | |
| SCHEMBL18361216 | 0.84 | HDAC1 (0.77) | HDAC1HDAC3HDAC2MAPK1NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105682655-A | Antimicrobial compounds | 阿克塞利亚制药公司 | 2016-06-15 | — | — | CN | claimed |
| CN-106966978-A | A kind of amides compound and its production and use | 北京化工大学 | 2017-07-21 | — | — | CN | disclosed |
| CN-105682655-A | Antimicrobial compounds | 阿克塞利亚制药公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-104208716-A | Cyclodextrin-based polymers for therapeutic delivery | CERULEAN PHARMA INC | 2014-12-17 | — | — | CN | disclosed |
| CN-103442563-A | cancer treatment | CERULEAN PHARMA INC | 2013-12-11 | — | — | CN | disclosed |
| CN-102781237-A | Cyclodextrin-based polymers for delivery of therapeutic agents | CERULEAN PHARMA INC | 2012-11-14 | — | — | CN | disclosed |
| EP-2413901-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | Cerulean Pharma Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010117668-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-1833500-A4 | METHOD TO ENHANCE THE BONE FORMATION ACTIVITY OF BMP BY RUNX2 ACETYLATION | BIORUNX CO LTD (KR) | 2009-08-12 | — | — | EP | disclosed |
| US-20080219962-A1 | Method to Enhance the Bone Formation Activity of Bmp by Runx2 Acetylation | BIORUNX CO., LTD. (KR) | 2008-09-11 | — | — | US | disclosed |
| EP-1833500-A1 | METHOD TO ENHANCE THE BONE FORMATION ACTIVITY OF BMP BY RUNX2 ACETYLATION | Biorunx Co., Ltd (KR) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006065075-A1 | METHOD TO ENHANCE THE BONE FORMATION ACTIVITY OF BMP BY RUNX2 ACETYLATION | BIORUNX CO. LTD. (KR) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080219962-A1 | Method to Enhance the Bone Formation Activity of Bmp by Runx2 Acetylation | BMP2, BMP1, BMP4 | HDAC1 28/4885HDAC3 118/4885HDAC2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.